When obese people with low growth hormone took a drug called tesamorelin for a year, their muscle energy recovery got better, which means their muscle cells may have become better at making energy.

In a 12-month randomized, double-blind, placebo-controlled trial, tesamorelin improved mitochondrial oxidative capacity in obese adults with reduced growth hormone secretion, as measured by enhanced phosphocreatine recovery after exercise, with improvements strongly associated with increased IGF-I levels.

In obese people with low growth hormone taking tesamorelin, higher IGF-I levels are linked to better mitochondrial energy efficiency, measured by τPCr.

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole group of participants.

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole study group.

In people who took tesamorelin, the more their IGF-I levels went up, the better their muscles recovered after exercise — and this link was even stronger than in the whole group.